Drug Trial Radar · NCT07937449
The Efficacy and Safety of DLBS3233 in Adults With Prediabetes
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Jul 7, 2025
Primary completion
Oct 15, 2026
Study completion Oct 15, 2026
Sponsor
- Lead sponsor
- Dexa Medica GroupIndustry
- Sponsor type
- Industry
- Collaborators
- PT Equilab International
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 3-arm, prospective, randomized, double-blind, parallel, controlled, non-inferiority study comparing DLBS3233 at a dose of 100 mg once daily; DLBS3233 at a dose of 200 mg once daily; and Metformin XR 500 mg twice daily for a 12-week course of therapy. DLBS3233 is a bioactive fraction derived from a combination of Lagerstroemia speciosa and Cinnamomum burmanii. DLBS3233 exhibits antidiabetic properties by enhancing insulin signaling, improving glucose uptake, modulating lipid metabolism, and reducing insulin resistance.
Conditions
- Prediabetes
Interventions
DLBS3233Drug
DLBS3233 will be given into two different groups; 1 capsule of DLBS3233 100 mg once daily and 2 capsules of DLBS3233 100 mg once daily.
Metformin XRDrug
Metformin XR 500 mg will be given 1 tablet twice daily as a comparator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes of HbA1c levelsTime frame: 12 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Department of Internal Medicine, Dr. Soetomo Regional Public Hospital
Surabaya, East Java, Indonesia
Equilab International
Jakarta, Jakarta Special Capital Region, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.